Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Merck
Express Scripts
Dow
Medtronic
Boehringer Ingelheim
Mallinckrodt

Last Updated: December 9, 2019

DrugPatentWatch Database Preview

PREMARIN Drug Profile

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

When do Premarin patents expire, and when can generic versions of Premarin launch?

Premarin is a drug marketed by Wyeth Pharms and is included in three NDAs.

The generic ingredient in PREMARIN is estrogens, conjugated. There are three drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the estrogens, conjugated profile page.

Drug patent expirations by year for PREMARIN
Drug Prices for PREMARIN

See drug prices for PREMARIN

Drug Sales Revenue Trends for PREMARIN

See drug sales revenues for PREMARIN

Recent Clinical Trials for PREMARIN

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
University of LouisvillePhase 4
PfizerPhase 1/Phase 2
University of PennsylvaniaPhase 1/Phase 2

See all PREMARIN clinical trials

Pharmacology for PREMARIN
Drug ClassEstrogen
Mechanism of ActionEstrogen Receptor Agonists
Synonyms for PREMARIN
1,3,5(10)-Estratrien-17-one 3-sulfate
1,3,5(10)-ESTRATRIEN-3-OL-17-ONE SULPHATE, SODIUM SALT
17-Oxoestra-1,3,5(10)-trien-3-yl sodium sulfate
438-67-5
481-97-0 (Parent)
6K6FDA543A
AC1Q1VL0
AKOS015967195
API0000550
C-53154
CCG-101163
CHEBI:8389
CHEMBL2106240
Conestoral
Conjugated estrogens: sodium estrone sulfate
CTK4I7843
D00312
EINECS 207-120-4
Estra-1,3,5(10)-trien-17-one, 3-(sulfooxy)-, sodium salt
Estra-1,3,5(10)-trien-17-one, 3-(sulfooxy)-, sodium salt (9CI)
Estra-1,3,5(10)-trien-17-one,3-(sulfooxy)-, sodium salt (1:1)
Estrogenic substances (conjugated)
Estrogens
Estrone 3-sulfate sodium salt
Estrone estrone hydrogen sulfate
ESTRONE SODIUM SULFATE
Estrone Sodium Sulfate [USAN]
Estrone sodium sulphate
Estrone sulfate sodium
Estrone sulfate sodium salt
Estrone-3-sulfate sodium salt
estrone-sulfate
Estrone, hydrogen sulfate, sodium salt
evex
HMS2052J05
HMS2232J23
Hyhorin
LS-64886
MFCD00070035
MLS000069757
MLS001424259
MolPort-005-940-816
Morestin
NC00413
NSC 18313
oestrone sulphate
Oestrone-3-sulphate sodium salt
Par Estro
potassium estrone 3-sulfate(1-)
Premarin tabs
Premarin Vaginal
Prempro/Premphase
SCHEMBL4616
SMR000058772
sodium (8R,9S,13S,14S)-13-methyl-17-oxo-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yl sulfate
sodium 17-oxoestra-1(10),2,4-trien-3-yl sulfate
Sodium estrone 3-sulfate
Sodium estrone sulfate
Sodium estrone-3-sulfate
UNII-3ASP8Q3768 component VUCAHVBMSFIGAI-ZFINNJDLSA-M
UNII-6K6FDA543A
UNII-8L6LAK9BTR component VUCAHVBMSFIGAI-ZFINNJDLSA-M
UNII-IU5QR144QX component VUCAHVBMSFIGAI-ZFINNJDLSA-M
UNII-JM2621P2LS component VUCAHVBMSFIGAI-ZFINNJDLSA-M
Paragraph IV (Patent) Challenges for PREMARIN
Tradename Dosage Ingredient NDA Submissiondate
PREMARIN TABLET;ORAL estrogens, conjugated 004782

US Patents and Regulatory Information for PREMARIN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Wyeth Pharms PREMARIN estrogens, conjugated CREAM;TOPICAL, VAGINAL 020216-001 Approved Prior to Jan 1, 1982 RX Yes Yes   Start Trial   Start Trial   Start Trial
Wyeth Pharms PREMARIN estrogens, conjugated TABLET;ORAL 004782-001 Approved Prior to Jan 1, 1982 RX Yes Yes   Start Trial   Start Trial   Start Trial
Wyeth Pharms PREMARIN estrogens, conjugated TABLET;ORAL 004782-006 Jul 16, 2003 RX Yes No   Start Trial   Start Trial   Start Trial
Wyeth Pharms PREMARIN estrogens, conjugated TABLET;ORAL 004782-002 Approved Prior to Jan 1, 1982 DISCN No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for PREMARIN

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Wyeth Pharms PREMARIN estrogens, conjugated TABLET;ORAL 004782-002 Approved Prior to Jan 1, 1982   Start Trial   Start Trial
Wyeth Pharms PREMARIN estrogens, conjugated CREAM;TOPICAL, VAGINAL 020216-001 Approved Prior to Jan 1, 1982   Start Trial   Start Trial
Wyeth Pharms PREMARIN estrogens, conjugated TABLET;ORAL 004782-001 Approved Prior to Jan 1, 1982   Start Trial   Start Trial
Wyeth Pharms PREMARIN estrogens, conjugated TABLET;ORAL 004782-004 Approved Prior to Jan 1, 1982   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Moodys
AstraZeneca
Johnson and Johnson
Baxter
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.